Profile
Dennis Hom worked as an Executive Director of Corporate Development at Amgen, Inc. from 2011 to 2012.
He then worked as a Vice President of Finance and Corporate Development at Achaogen, Inc. from 2013 to 2014.
Currently, he is the CFO and Head of Corporate Development at Sagimet Biosciences, Inc. starting from 2017 and continuing until 2023.
Hom received his undergraduate degree from the Massachusetts Institute of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-07-17 | 0 ( -.--% ) | - $ | 2024-03-30 |
Former positions of Dennis Hom
| Companies | Position | End |
|---|---|---|
| SAGIMET BIOSCIENCES INC. | Director of Finance/CFO | 2023-07-31 |
| ACHAOGEN | Director of Finance/CFO | 2014-03-30 |
| AMGEN INC. | Corporate Officer/Principal | 2011-12-31 |
Training of Dennis Hom
| Massachusetts Institute of Technology | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| SAGIMET BIOSCIENCES INC. | Health Technology |
| Private companies | 1 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Dennis Hom
